ReviewPeripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies
Introduction
Guillain–Barré syndrome (GBS), characterized by the acute flaccid paralysis, consists of 2 major subtypes, acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN) [1], [2]. Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterized by progressive limb weakness over 8 weeks and is regarded as the chronic counterpart of GBS [3]. AIDP was originally presumed to be a T-cell–mediated disease [4]. However, complement deposits along the outer surface of Schwann cells without any T-cells at the peripheral nerves in some AIDP patients, suggesting that autoantibodies to myelin antigens activate complement and cause demyelination [5]. Plasma exchange is effective for GBS and CIDP, indicating that humoral factors such as autoantibodies participate in both conditions [2], [3].
In AMAN, Miller Fisher syndrome and acute ataxic neuropathy, it is currently established that gangliosides are the target antigens of autoantibodies [[2], [6]]. Gangliosides are expressed on the axonal membrane and in the myelin in the peripheral nervous system (PNS) [7]. IgG anti-GM1 and anti-GD1a antibodies are strongly associated with AMAN [8], [9]. IgG and complement deposits are observed at the nodal axolemma in the spinal anterior roots in patients with AMAN [5], as well as in animal model of AMAN [10]. Passive transfer of the IgG anti-GM1 or anti-GD1a antibodies along with complement produces a replica of AMAN [11], [12]: these studies have established that the IgG anti-GM1 and anti-GD1a antibodies are pathogenic autoantibodies in AMAN.
In AIDP and CIDP, the implication of anti-gangliosides antibodies is not as well established. Monospecific IgG anti-GD1b antibodies were found in patients with AIDP in a study by Miyazaki et al. [13], but this was not confirmed by other studies [14], [15]. In a report, 2 patients with AIDP or CIDP had elevated titers of IgG anti-GD3 antibodies [16], but such antibodies are more commonly associated with Miller Fisher syndrome [17]. IgG anti-LM1 antibodies were also found in AIDP patients [13]. However, AMAN patients have a higher prevalence of IgG anti-LM1 antibodies than AIDP, and larger studies are needed to determine the association of monospecific IgG anti-LM1 antibodies in AIDP [18].
Altogether, these results suggest that autoantibodies directed against axonal gangliosides do not have a direct implication in the pathogenesis of AIDP and CIDP; rather, the hallmarks of demyelination in these neuropathies suggest that autoantibodies are directed against proteins expressed on Schwann cells. Here, we critically review the pathological implication of various autoantibodies reported in AIDP or CIDP, and suggest new putative antigens based on the understanding of the function of these molecules in myelination and in hereditary demyelinating neuropathies. We will focus this review on molecules presenting extracellular domains, as these are more likely to be relevant targets of autoantibodies [19]. For instance, IgG against moesin, a cytosolic component of the microvilli surrounding the nodes, has been detected in patients with cytomegalovirus-related AIDP during the acute phase of the illness [20]. However, our attempt to reproduce these results using enzyme-linked immunosorbent assay failed to demonstrate the presence of autoantibodies against the ezrin, radixin and moesin (Miyaji and Yuki, unpublished data). This emphasizes that future studies on antibodies against intracellular molecules should be warranted [19]. Given the large heterogeneity of AIDP and CIDP, the determination of the immune targets in these diseases is a high priority goal, which may help define more efficacious treatments [21].
Section snippets
Immunity to myelin components implicated in experimental autoimmune neuritis (EAN)
The study of the autoimmune mechanisms involved in EAN, an animal model of GBS, has first motivated the search for autoantigens in peripheral nerve. EAN was first produced in rabbits by immunization against whole peripheral nerve homogenates [22]. Compact myelin proteins, P0 glycoprotein, P2 basic protein, and peripheral myelin protein 22 (PMP22) are the main antigens producing EAN in rabbits or guinea pigs [23], [24].
P2 is a cytosolic protein of the PNS myelin. Immunization against synthetic
Immunity to nodal, paranodal and juxtaparanodal proteins in neuropathies
Cell adhesion molecules not only play an important function in myelin formation, but also in the organization of the axonal domains such as the nodes of Ranvier, paranodes and juxtaparanodes [[118], [119]] (Fig.1). The specific axoglial interactions mediated by cell adhesion molecules are crucial for maintaining the integrity and normal function of the myelinated axon, and particularly for the rapid saltatory propagation of the action potential. Disruption of these nodal, paranodal and
Conclusion
The findings of autoantibodies to gangliosides, myelin proteins, nodal and paranodal proteins have strongly suggested that the pathogenesis of GBS and CIDP is immune-mediated. Despite advances in the diagnosis and treatment of GBS and CIDP, the antigenic targets in AIDP and CIDP remain largely unknown. The nodal, paranodal and juxtaparanodal proteins seem to be antigenic targets in AIDP and CIDP. Proteins implicated in other demyelinating neuropathies such as CMT need to be further explored and
Take-home message
- •
AIDP and CIDP are heterogenous diseases, thus the identification of novel biomarkers shall help the treatment of these pathologies.
Acknowledgments
This review was financially supported by the Singapore Medical Research Council (IRG 10nov086, R-172-000-263-213 and CSA/047/2012, R-172-000-286-511) from the Singapore Ministry of Health.
References (133)
- et al.
Guillain–Barré syndrome and other immune mediated neuropathies: diagnosis and classification
Autoimmun Rev
(2014) - et al.
Guillain–Barré syndrome
N Engl J Med
(2012) - et al.
Chronic inflammatory demyelinating polyneuropathy
N Engl J Med
(2005) - et al.
The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis
Medicine (Baltimore)
(1969) - et al.
Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy
Ann Neurol
(1996) - et al.
Acute and chronic ataxic neuropathies with disialosyl antibodies: a continuous clinical spectrum and a common pathophysiological mechanism
Muscle Nerve
(2014) - et al.
Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord
Biochim Biophys Acta
(1994) - et al.
Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis
Neurology
(1990) - et al.
Anti‐GD1a antibody is associated with axonal but not demyelinating forms of Guillain–Barré syndrome
Ann Neurol
(1999) - et al.
Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers
J Neurol Sci
(2007)
The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice
J Clin Invest
Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy
J Neurosci
Guillain–Barré syndrome associated with IgG monospecific to ganglioside GD1b
Neurology
Conduction block in acute motor axonal neuropathy
Brain
Antiganglioside antibodies are associated with axonal Guillain–Barré syndrome: a Japanese–Italian collaborative study
J Neurol Neurosurg Psychiatry
AIDP and CIDP having specific antibodies to the carbohydrate epitope (-NeuAcalpha2-8NeuAcalpha2-3Galbeta1-4Glc-) of gangliosides
J Neurol Sci
Antibodies to GD3, GT3, and O-acetylated species in Guillain–Barré and Fisher's syndromes: their association with cranial nerve dysfunction
J Neurol Sci
Fine specificities of anti-LM1 IgG antibodies in Guillain–Barré syndrome
J Neurol Sci
Neuronal autoantigens-pathogenesis, associated disorders and antibody testing
Nat Rev Neurol
Moesin is a possible target molecule for cytomegalovirus-related Guillain–Barré syndrome
Neurology
Autoimmune diseases of the peripheral nervous system
Autoimmun Rev
Identification of the neuritogen for experimental allergic neuritis
Nature
The P2 protein of bovine root myelin: isolation and some clinical and immunological properties
J Neurochem
Experimental allergic neuritis: evidence for the involvement of the P0 and P2 proteins
Brain Res
Evolution of the cellular response in P2-induced experimental allergic neuritis
Pathobiology
Immune reactions to P2 protein in human inflammatory demyelinative neuropathies
Neurology
Inherited demyelinating neuropathies: from gene to disease
Curr Opin Neurol
Antibody responses to P0 and P2 myelin proteins in Guillain–Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy
J Neuroimmunol
P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy
Ann Neurol
Investigation of serum response to PMP22, connexin 32 and P0 in inflammatory neuropathies
J Neuroimmunol
Induction of experimental autoimmune neuritis with peripheral myelin protein-22
Brain
Molecular cell biology of Charcot–Marie–Tooth disease
Neurogenetics
Hereditary predominantly motor neuropathies
Curr Opin Neurol
Peripheral myelin protein 22 gene maps in the duplication in chromosome 17p11. 2 associated with Charcot–Marie–Tooth 1A
Nat Genet
Prednisone-responsive hereditary motor and sensory neuropathy
Mayo Clin Proc
Chronic inflammatory demyelinating polyneuropathy caused by HIV infection in a patient with asymptomatic CMT 1A
J Peripher Nerv Syst
Coexistent hereditary and inflammatory neuropathy
Brain
CMTX mimicking childhood chronic inflammatory demyelinating neuropathy with tremor
Muscle Nerve
A family with IVIg-responsive Charcot–Marie–Tooth disease
J Neurol
Anti-PMP22 antibodies in patients with inflammatory neuropathy
J Neuroimmunol
Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies
J Neuroimmunol
Periaxin expression in myelinating Schwann cells: modulation by axon-glial interactions and polarized localization during development
Development
Antibodies to L-periaxin in sera of patients with peripheral neuropathy produce experimental sensory nerve conduction deficits
J Neurochem
Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy
J Neurol Neurosurg Psychiatry
Immune responses to myelin proteins in Guillain–Barré syndrome
J Neurol Neurosurg Psychiatry
Immune responses to myelin antigens in Guillain–Barré syndrome
J Neuroimmunol
Study of antibodies to PMP22, IL-6 and TNF-alpha concentrations in serum in a CMTX1 family
Neurosci Lett
Nodal proteins are target antigens in Guillain–Barré syndrome
J Peripher Nerv Syst
Neurofascin as a target for autoantibodies in peripheral neuropathies
Neurology
Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy
Ann Neurol
Cited by (29)
Pediatric-Onset Chronic Inflammatory Demyelinating Polyneuropathy: A Multicenter Study
2023, Pediatric NeurologyImmunohistochemistry and electrophysiological findings in swine abattoir workers with immune-mediated polyradiculoneuropathy
2018, Journal of the Neurological SciencesCitation Excerpt :This pattern would typically be interpreted as being consistent with primary demyelination, and the distribution is that of radiculoneuropathy, as is seen in the most common form of Guillain-Barré syndrome (GBS; acute, inflammatory, demyelinating polyneuropathy). Nodal proteins have recently been investigated as the site of pathology in both GBS and chronic inflammatory demyelinating polyneuropathy (CIDP) [6,7]. Gliomedin, contactin, and neurofascin are nodal and paranodal proteins that may incite antibodies in some of these patients [8–10].
What is new in 2015 in dysimmune neuropathies?
2016, Revue NeurologiqueCitation Excerpt :In another study, this group also showed that vinculin is a possible immunological target molecule in a subpopulation of typical CIDP patient [33]. A review highlighted the importance of autoantibodies to peripheral nerve proteins in the physiopathology of acute and chronic inflammatory demyelinating polyneuropathies [34], and another the role of persistent leukocyte trafficking across the blood-nerve barrier [3]. There is some possibility of NK cell function being an important factor in the pathogenesis of CIDP [35], and perforin (PRF) has a key role in the function of cytotoxic T and natural killer cells [36].
Guillain-Barré syndrome
2016, The LancetCitation Excerpt :The diagnosis is largely based on clinical patterns, because diagnostic biomarkers are not available for most variants of the syndrome. Identification of biomarkers and establishment of their pathophysiological roles, if any, in experimental models has been a major research challenge.9,10 All patients with Guillain-Barré syndrome need meticulous monitoring and supportive care.11